このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Omeros 将来の成長

Future 基準チェック /26

Omerosは、37%と61.6%でそれぞれ年率37%で利益と収益が成長すると予測される一方、EPSはgrowで41.5%年率。

主要情報

38.2%

収益成長率

42.5%

EPS成長率

Pharmaceuticals 収益成長	23.5%
収益成長率	65.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	09 Aug 2024

今後の成長に関する最新情報

Recent updates

Should Shareholders Reconsider Omeros Corporation's (NASDAQ:OMER) CEO Compensation Package?

Jun 05

Omeros posts preliminary results from COVID-19 patients treated with narsoplimab

May 28

CDC and CMS OKs Omeros' ICD-10 codes for HSCT-TMA diagnosis and narsoplimab

May 04

What Kind Of Shareholders Own Omeros Corporation (NASDAQ:OMER)?

Mar 03

業績と収益の成長予測

NasdaqGM:OMER - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	26	-134	N/A	N/A	2
12/31/2025	8	-156	N/A	N/A	2
12/31/2024	N/A	-176	N/A	N/A	2
6/30/2024	N/A	-200	-156	-155	N/A
3/31/2024	N/A	-179	-142	-142	N/A
12/31/2023	N/A	-175	74	75	N/A
9/30/2023	N/A	-182	84	84	N/A
6/30/2023	N/A	-185	90	90	N/A
3/31/2023	N/A	-182	103	103	N/A
12/31/2022	N/A	-182	-87	-86	N/A
9/30/2022	N/A	-183	-79	-79	N/A
6/30/2022	N/A	-173	-77	-77	N/A
3/31/2022	N/A	-181	-85	-85	N/A
12/31/2021	N/A	-192	-110	-110	N/A
9/30/2021	-63	-217	-110	-110	N/A
6/30/2021	-37	-211	-121	-121	N/A
3/31/2021	-24	-194	-131	-131	N/A
12/31/2020	N/A	-173	-100	-100	N/A
9/30/2020	97	-130	-105	-105	N/A
6/30/2020	100	-108	-78	-77	N/A
3/31/2020	114	-89	-56	-56	N/A
12/31/2019	N/A	-147	-60	-60	N/A
9/30/2019	100	-79	-62	-62	N/A
6/30/2019	75	-102	-92	-91	N/A
3/31/2019	50	-121	-106	-105	N/A
12/31/2018	30	-127	-104	-104	N/A
9/30/2018	22	-120	-84	-83	N/A
6/30/2018	39	-88	-58	-58	N/A
3/31/2018	54	-68	N/A	-35	N/A
12/31/2017	65	-53	N/A	-36	N/A
9/30/2017	64	-57	N/A	-43	N/A
6/30/2017	54	-63	N/A	-43	N/A
3/31/2017	46	-61	N/A	-48	N/A
12/31/2016	42	-67	N/A	-52	N/A
9/30/2016	35	-67	N/A	-57	N/A
6/30/2016	27	-73	N/A	-61	N/A
3/31/2016	21	-77	N/A	-64	N/A
12/31/2015	14	-75	N/A	-65	N/A
9/30/2015	7	-76	N/A	-64	N/A
6/30/2015	4	-74	N/A	-66	N/A
3/31/2015	1	-76	N/A	-64	N/A
12/31/2014	1	-74	N/A	-58	N/A
9/30/2014	1	-55	N/A	-43	N/A
6/30/2014	1	-50	N/A	-38	N/A
3/31/2014	1	-46	N/A	-32	N/A
12/31/2013	2	-40	N/A	-30	N/A
9/30/2013	3	-46	N/A	-42	N/A

アナリストによる今後の成長予測

収入対貯蓄率: OMER今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: OMER今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: OMER今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: OMERの収益 ( 61.6% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: OMERの収益 ( 61.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: OMERの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Omeros 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target decreased by 17% to US$5.83

Price target increased by 17% to US$7.00

No longer forecast to breakeven

Consensus revenue estimates increase by 113%

Price target increased to US$16.00

Consensus revenue estimates fall by 35%

Recent updates

Omeros Corporation to Report Q2, 2024 Results on Aug 07, 2024

Omeros: Troubled Company Working Its Way Out Of The Morass

Omeros Corporation Announces Executive Changes

Omeros Corporation announced that it expects to receive $92.1 million in funding

Omeros Corporation to Report Q1, 2024 Results on May 15, 2024

Omeros Corporation, Annual General Meeting, Jun 06, 2024

Omeros Corporation (NasdaqGM:OMER) announces an Equity Buyback for $50 million worth of its shares.

Omeros Corporation to Report Q4, 2023 Results on Apr 01, 2024

Omeros: Still Worth A Look Despite Narsoplimab Woes

New major risk - Share price stability

New major risk - Negative shareholders equity

Omeros Corporation to Report Q3, 2023 Results on Nov 09, 2023

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Price target decreased by 17% to US$5.83

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

New minor risk - Market cap size

Omeros Corporation to Report Q2, 2023 Results on Aug 09, 2023

Is Omeros (NASDAQ:OMER) A Risky Investment?

Omeros Corporation, Annual General Meeting, Jun 23, 2023

Kurt Zumwalt Not to Stand for Re-Election as Class II Director of Omeros Corporation

Omeros Corporation to Report Q1, 2023 Results on May 09, 2023

Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt

Price target increased by 17% to US$7.00

No longer forecast to breakeven

Consensus revenue estimates increase by 113%

Insufficient new directors

Omeros Corporation to Report Q3, 2022 Results on Nov 09, 2022

Omeros: Taking It To The Max

Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

Omeros falls 11% after reporting clinical data for COVID-19 therapy

Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

Omeros: Managing An Investment After A Winning Trade

Omeros Corporation to Report Q2, 2022 Results on Aug 09, 2022

Omeros granted FDA’s Orphan Drug designation for PNH candidate

Omeros: Follow The Bouncing Ball

Price target increased to US$16.00

Omeros: On Death's Door

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.57 loss in 1Q 2021)

Omeros Corporation to Report Q1, 2022 Results on May 10, 2022

Consensus revenue estimates fall by 35%

No longer forecast to breakeven

Omeros Corporation, Annual General Meeting, Jun 17, 2022

Omeros: The Weight Of The Wait, A Conundrum

Insufficient new directors

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Insufficient new directors

Omeros Corporation to Report Q4, 2021 Results on Mar 01, 2022

Omeros: Despite Its Promise, The CRL Is A Huge Obstacle

Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA

Price target decreased to US$15.00

Forecast to breakeven in 2024

Rayner Surgical Inc. completed the acquisition of OMIDRIA Franchise from Omeros Corporation (NasdaqGM:OMER).

Omeros: A New Year Beckons

Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates

Consensus revenue estimates increase to US$129.6m

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.66 loss in 3Q 2020)

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.66 loss in 3Q 2020)

Price target decreased to US$22.50

Omeros: What's Left

Price target decreased to US$25.29

Omeros: The Prize Is Nigh (Again)

Independent Director exercised options to buy US$156k worth of stock.

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.61 loss in 2Q 2020)

Omeros: PDUFA Delay Presents An Opportunity

Co-Founder exercised options and sold US$801k worth of stock

Omeros Corporation Announces Narsoplimab Pivotal Trial Data in Oral Presentation at 2021 Annual Congress of the European Hematology Association